Fig. 6: Inhalation of mnbTSLP-iLNPBUD5 resolves airway inflammation and improves pulmonary function in severe asthmatic mice. | Nature Communications

Fig. 6: Inhalation of mnbTSLP-iLNPBUD5 resolves airway inflammation and improves pulmonary function in severe asthmatic mice.

From: Budesonide-incorporated inhalable lipid nanoparticles for antiTSLP nanobody mRNA delivery to treat steroid-resistant asthma

Fig. 6

a–c, Eosinophils (a), neutrophils (b), and macrophages (c) counts in the BALF of mice following the indicated treatments were assessed using a Diff-Quik stain kit. d–h, ELISA analysis of IL-4 (d), IL-5 (e), IL-13 (f), TSLP (g), and IL-6 (h) levels in the BALF collected from the mice receiving the indicated treatments. i IgE levels in the serum collected from the mice receiving the indicated treatments, determined by ELISA assay. j, k The elastance (j) and airway resistance (k) of the mice subjected to the indicated treatments were assessed using the SCIREQ flexiVent system following stimulation with various concentrations of methacholine. Results are presented as mean ± s.d, n = 5 biologically independent mice per group a–k. Significant differences were assessed using a one-way ANOVA with Tukey’s multiple comparisons test a–i or by Two-way ANOVA with Tukey’s multiple comparisons test j, k. Source data are provided as a Source Data file.

Back to article page